Anticancer Drugs 2005,16(5):551–557 CrossRef 21 Alexander BL, Al

Anticancer Drugs 2005,16(5):551–557.CrossRef 21. Alexander BL, Ali RR, Alton EW, Bainbridge JW, Braun S, Cheng SH, Flotte TR, Gaspar HB, Grez M, Griesenbach U, Kaplitt MG, Ott MG, Seger R, Simons M, Thrasher AJ, Thrasher AZ, Ylä-Herttuala S: Progress and prospects: gene therapy clinical trials

(part 1). Gene Ther 2007, 20:1439–1447. 22. Guinn BA, Mulherkar R: International progress in cancer gene therapy. Cancer Gene Ther 2008, 12:765–775.CrossRef 23. Scherer L, Rossi JJ, Weinberg MS: Progress and prospects: RNA-based therapies for treatment of HIV infection. Gene Ther 2007, 14:1057–1064.CrossRef 24. Androic I, Krämer A, Yan R, Rödel F, Gätje R, Kaufmann M, Strebhardt K, Yuan J: Targeting cyclin B1 inhibits check details proliferation and sensitizes breast cancer cells to taxol. BMC Cancer 2008, 8:391.CrossRef 25. Brun A, Albina E, Barret T, Chapman DA, Czub M, Dixon LK, Keil GM, Klonjkowski B, Le Potier MF, Libeau G, Ortego J, Richardson

J, Takamatsu HH: Antigen delivery systems for veterinary vaccine development. Viral-vector based delivery systems. Vaccine 2007, 26:6508–6528.CrossRef 26. Nafee N, Taetz S, Schneider M, Schaefer UF, Lehr CM: Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides. Nanomedicine 2007, 3:173–183.CrossRef 27. Geusens B, Lambert J, De Smedt SC, LY2874455 Buyens K, Sanders NN, Van Gele M: Ultradeformable PI3K inhibitor cationic liposomes for delivery of small interfering RNA (siRNA) into human primary melanocytes. J Control Release 2009, 133:214–220.CrossRef 28. Zhou J, Wu J, Hafdi N, Behr JP, Erbacher P, Peng L: PAMAM dendrimers for efficient siRNA delivery and potent gene silencing. Chem Commun 2006, 22:2362–2364.CrossRef 29. Park TG, Jeong JH, Kim SW: Current status of polymeric gene delivery

systems. Adv Drug Deliv Rev 2006, 58:467–486.CrossRef 30. Son S, Kim WJ: Biodegradable nanoparticles modified by branched polyethylenimine for plasmid DNA delivery. Biomaterials 2010, 31:133–143.CrossRef 31. Blum JS, Saltzman WM: High loading efficiency and tunable release of plasmid cAMP DNA encapsulated in submicron particles fabricated from PLGA conjugated with poly-L-lysine. J Control Release 2008, 129:66–72.CrossRef 32. Dewey RA, Morrissey G, Cowsill CM, Stone D, Bolognani F, Dodd NJ, Southgate TD, Klatzmann D, Lassmann H, Castro MG, Löwenstein PR: Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus mediated gene therapy: implications for clinical trials. Nat Med 1999, 11:1256–1263.CrossRef 33. Huang H, Yu H, Tang G, Wang Q, Li J: Low molecular weight polyethylenimine cross-linked by 2-hydroxypropyl-gamma-cyclodextrin coupled to peptide targeting HER2 as a gene delivery vector. Biomaterials 2010,31(7):1830–1838.CrossRef 34.

Related posts:

  1. custom peptide priceAG 879 induces apoptosis development of anticancer drugs
  2. J Appl Phys 2005,98(7):074904 CrossRef 25 Deal BE, Grove AS: Gen
  3. J

    Appl Phys 1998,84(11): 6023–6026 CrossRef 18 Hobbs RG,
  4. Bioinformatics 2005, 21:3797–3800 CrossRef 17 Tcherepanov V, Ehl
  5. CrossRef
This entry was posted in Antibody. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>